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A NEW ONCOGENIC FUNCTION OF THE GLYCOLYTIC ENZYME 
LACTATE DEHYDROGENASE-A IN SMALL CELL LUNG CANCER 
TOBIN GRAMYK 
ABSTRACT 
 Small Cell Lung Cancer (SCLC) is an epithelial cancer that has, until recent 
years, been labeled a recalcitrant tumor type. Since its discovery and classification, there 
has been very little research to understand and treat SCLC.  Conventional methods of 
treatment for SCLC include chemotherapeutics have been used with little long-term 
success. Following initial treatment, the cancer appears to be fully wiped out, however 
seemingly without fail the cancer reemerges with acquired drug resistance and the 
capability to rapidly metastasize, leading to a five-year survival rate of less than 10%. 
While there have been continuous improvements in the field of cancer therapeutics, 
combining chemotherapeutics and immunotherapy, there has been no targeted clinical 
therapy for SCLC. Recent studies have suggested that an acidic tumor microenvironment 
is highly important for the progression of other cancers. LDHA generates lactate from 
pyruvate, leading to a more acidic environment, which indicates LDHA may be a viable 
target for cancer therapeutics. CRISPR-cas9 gene editing and mouse SCLC cell lines 
were used to study lactate concentration and cell vitality. After analysis of several 
different SCLC tumors, larger tumors had both a higher metastatic capability and higher 
concentrations of lactate, indicating that LDHA was more highly active in these tumors. 
CRISPR-cas9 knockout targeting of LDHA decreased SCLC colony formation and 
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cellular growth in vitro, leading to the conclusion that LDHA may play a vital role in the 
future as a potential therapeutic target for the treatment of SCLC.  
  
  vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES ........................................................................................................... viii 
LIST OF FIGURES ........................................................................................................... ix 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1 
SPECIFIC AIMS .............................................................................................................. 15 
METHODS ....................................................................................................................... 16 
RESULTS ......................................................................................................................... 24 
DISCUSSION ................................................................................................................... 37 
REFERENCES ................................................................................................................. 42 
VITA ................................................................................................................................. 49 
 
  
  viii 
LIST OF TABLES 
 
 
Table Title Page 
1 List of Primers used for enzyme cutting in plasmid design 17 
2 Concentration of pCDH Plasmids before ligation 23 
3 Protein Concentration of MCF-7 hLDHA sgRNA cells 24 
   
   
   
 
 
  
  ix 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Schematic Diagram of Glycolysis  5 
2 HIF1a and LDHA Interaction 7 
3 Protein Detection of hLDHA sgRNA in MCF-7 Cells 24 
4 Western Blot of 2-day Puromycin Selection MCF-7 Cells 25 
5 Western Blot of hLDHA-KO in MCF-7 and A549 Cells 26 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
IF Staining of A549 WT Cells in Full Medium 
IF Staining of A549 WT Cells with Lactate Treatment 
IF Staining of A549 CRISPR V2 Cells in Full Medium 
IF Staining of A549 CRISPR V2 Cells Lactate Treatment 
IF Staining of A549 hLDHA sg1 in Full Medium 
Translocation of LDHA into the Nucleus 
Concentration of Lactate in Different Sized Tumors 
Expression of LDHA in 716T2S Cell Line 
Lactate Concentration in Mouse SCLC Cells 
Western Blot of LDHA-KO in Mouse SCLC Cells 
Lactate Concentration in 716T2S-LDHA-KO Cells 
Colony Formation of 716T2S-LDHA-KO cells 
Colony Counting of 716T2S-LDHA-KO Cells 
26 
27 
27 
28 
28 
29 
30 
31 
31 
32 
32 
33 
33 
  x 
19 
20 
21 
22 
23 
Cellular Growth of 716T2S-LDHA-KO Cells 
Western Blot of 728N-LDHA-KO Cells 
Colony Formation of 728N-LDHA-KO Cells 
Colony Counting of 728N-LDHA-KO Cells 
Cellular Growth of 728N-LDHA-KO Cells 
34 
34 
35 
35 
36 
 
 
  
  xi 
LIST OF ABBREVIATIONS 
 
BU ............................................................................................................ Boston University 
CRISPR .................................  Clustered Regularly Interspaced Short Palindromic Repeats 
dNTP .............................................................................. Deoxyribonucleotide Triphosphate 
HRP .................................................................................................. Horseradish Peroxidase 
KO ........................................................................................................................ Knock Out 
LDHA .......................................................................................... Lactate Dehydrogenase A 
PCR ........................................................................................... Polymerase Chain Reaction 
SCLC..........................................................................Small Cell Lung Carcinoma (Cancer) 
WT ....................................................................................................................... Wild Type 
 
 1 
INTRODUCTION 
 Cancer is the cause of about twenty-five percent of deaths in the United States. 
Frustratingly, there is a rise in the number of incidences of cancer, mainly due to an 
increased population size, a higher life expectancy, and various other risk factors such as 
smoking, decreased activity, and a rise in obesity. Globally, breast cancer is diagnosed 
the most frequently in females and similarly it is the cancer that has the highest death rate 
among females. In Northern America, there is an elevated incidence of breast cancer, and 
currently there are no direct cures for this cancer (Torre et al., 2015). Cancer is marked 
by several factors found throughout its development. There is a contemporary list of six 
hallmarks of cancer that include: Ongoing proliferative signaling, evasion of growth 
suppressors, resistance to cell death, unending replication, the induction of angiogenesis, 
and the ability to invade and metastasize to different tissues. Furthermore, these 
hallmarks are found with genomic instability which provides fertile ground for continued 
mutations that generate genetic diversity which in turn support the hallmarks of cancer. 
Recently, two new functions have become entwined in cancer; the distorted energy 
metabolism found in cancers as well as the ability to avoid destruction by the immune 
system. Additionally, it has been discovered that the microenvironment surrounding the 
tumor differs from the normal environment, still utilizing seemingly normal cells to 
create a healthier environment for the tumor (Hanahan & Weinberg, 2011). More 
specifically, a creation of metabolism specific hallmarks of cancer has been established. 
Among these metabolic hallmarks are: the dysregulated uptake of glucose and amino 
acids, utilization of wolfish methods to acquire nutrients, taking advantage of metabolic 
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intermediates for biosynthesis and generation of NADPH, a higher need for nitrogen, 
changes in gene regulation driven by metabolites, and the specific interactions between 
the microenvironment and the metabolites. Identification and further classification of 
these hallmarks is a point of continued research in the cancer field. The hope is that 
additional knowledge will elucidate novel targets for targeted therapy and the eventual 
cure to cancer (Pavlova & Thompson, 2016).  
 Glycolysis is an important source of ATP in many organisms. While it is not as 
efficient as aerobic respiration in terms of generating ATP, it has been found to play an 
important role in cancers. The enzymes involved in the biochemical pathway of 
glycolysis have been shown to have secondary functions that were previously unknown. 
LDHA, previously known to oxidize NADH to NAD
+
 through reduction of pyruvate to 
lactate has now been shown to have a role in transcriptional regulation of Histone 2B. 
This secondary role opens the door to examine the interaction between a glycolytic 
enzyme, such as LDHA, and its potential role in cancer (Kim & Dang, 2005).  Under 
normal conditions, LDH is expressed in both skeletal and cardiac muscle. It is comprised 
of two separate isoenzymes in a tetrameric arrangement. The two subunits are M and H. 
In total, there are five different combinations that have been completely characterized, 
that vary in the amount of each subunit present. Each isoform of LDH is a tetramer, that 
differs in the composition of subunits; in total there are five classified isoforms (Markert, 
1963) (Seth et al., 2011).  LDHA is comprised of four M subunits and is the form most 
commonly found in skeletal muscles. LDHB consists of four H subunits and is found in 
the heart. LDHA and LDHB have different characteristics and function differently. 
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LDHA is not inhibited by high concentrations of pyruvate whereas LDHB is inhibited by 
high concentrations of pyruvate. This difference indicates that LDHA is the isoform that  
preferentially produces lactate while LDHB preferentially produces pyruvate (Gray, 
Tompkins, & Taylor, 2014). An interesting phenomenon found in cancer cells is the use 
of glycolysis in the presence of ample oxygen. This was first identified by Otto Warburg 
and labeled “The Warburg Effect” or Aerobic Glycolysis (Liberti & Locasale, 2016) 
(Ždralević et al., 2018). Normal cells will primarily use oxidative phosphorylation as the 
main source of ATP generation as it is vastly more efficient and has a higher capacity for 
creation. The purpose of this aerobic glycolysis is still debated, but a compelling 
argument for its function has recently emerged. It is proposed that aerobic glycolysis is 
utilized by cancer cells, as well as other proliferating cells, to promote the uptake and 
subsequent incorporation of the required nutrients for growth into the cell biomass (Parra-
Bonilla, Alvarez, Al-Mehdi, Alexeyev, & Stevens, 2010). The reasoning supporting this 
idea is found in the activation of signaling pathways for cell proliferation also plays a role 
in regulating the metabolic pathways that control nutrient uptake, as well as specific 
mutations found in cancer cells that give them the ability to better proliferate rather than 
have efficient ATP generation. The proliferation of a normal cell is controlled by the 
presence of growth factors, as without these growth factors, normal cells cannot 
proliferate uncontrollably. It is found that cancer cells develop a genetic mutation that 
changes the growth factor signaling pathway in such a way that the cell will continuously 
uptake nutrients required for cell growth. The most important factor that is taken into the 
cell and metabolized is, of course, glucose (Vander Heiden, Cantley, & Thompson, 
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2009). The mechanism of this uptake is found in the upregulation in several key 
components of the glycolytic pathway. First, to get the glucose into the cell, there is an 
upregulation in the glucose transports GLUT 1 and GLUT 3. Second, an important 
enzyme isoform, Hexokinase II will interact with the mitochondria via a voltage-
dependent anionic channel. Third, Phosphofructokinase becomes overactive as it’s L and 
P isoforms predominate and the overexpression of PFKB3 causes higher levels of 
fructose-2,6-biphosphate which serve to further enhance the activity of PFK. Fourth, 
another isoform of Pyruvate kinase, M2, is responsible for regulation of the glycolytic 
flux and enhances metabolite accumulation within the cell to meet its growth needs. 
Importantly, the M-isoform of LDH is overexpressed, which will lead to a build-up of 
lactate and more acidic pH. Lastly, other mutations in the glycolytic pathway will disrupt 
transport of metabolites into the mitochondria as well as decrease the ability of the 
mitochondrial respiratory complexes to generate ATP (Fadaka et al., 2017). 
Figure 1: Schematic diagram of Glycolysis. In bold is the enzyme of importance in this 
study, LDH. LDH catalyzes the conversion of the reversible reaction of Pyruvate, the 
final result of glycolysis, into Lactate.  
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 Hypoxia is a common element found in cancer cells. This is due to the rapid 
growth of the cancer cells as they outgrow the capacity of their vascular supply, which 
thereby limits the amount of oxygen that is able to diffuse into the tumor. Cancer cells 
have developed methods to combat this, and often times cancers show increased 
expression of Hypoxia Induced Factor 1α (HIF1α) (Masoud & Li, 2015) (Rhim, Lee, & 
Lee, 2013). Interestingly, this expression is also increased in a hypoxia-independent 
mechanism, done by the master regulator MYC. Both hypoxic conditions and the 
oncogenic activity of the MYC increase the LDHA expression in cells. Additionally, 
activation of MYC causes an increase in the expression of a GLUT1 transporter that is 
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responsible for the uptake of glucose into the cell (Osthus et al., 2000). MYC has been 
implicated in other studies as having the ability to upregulate other glycolytic enzymes 
such as Hexokinase II, Phosphofructokinase, and Enolase 1. The upregulation of these 
enzymes contributes to the Warburg effect and has been postulated to increase the 
cellular invasion capability of cancer cells. Interestingly, it was found that MYC 
upregulation produced lactic acid and only LDHA upregulation produced increased levels 
of lactate, pointing to LDHA as a promotor of the Warburg effect. (Miller, Thomas, 
Islam, Muench, & Sedoris, 2012). This points to one hallmark of cancer, which is the 
changed metabolism (Majmundar, Wong, & Simon, 2010).  
Figure 2: HIF1A and LDHA Interaction. HIF1A is upregulated by hypoxic conditions 
in the cell as well as by MYC in a non-hypoxia dependent manner. Activation of HIF1A 
causes an increase in the expression of LDHA, which favors the production of Lactate 
and creates an increasingly acidic microenvironment around the cell. 
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 Tumor hypoxia has also been found to stimulate an epithelial-to-mesenchymal 
transition (EMT), which increases the metastatic capacity of the tumor as well as cellular 
mobility. It has also been posited that this transition also provides the cancer cells with 
increased drug resistance through its ability to stimulate cell quiescence (Muz, de la 
Puente, Azab, & Azab, 2015). LDH has been shown to be involved with the OCA-S 
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complex, which is a co-activation complex which is important in the activation of the 
Histone H2B Promoter. The importance of this relation between the two is found in the 
OCA-S complex’s location inside of the nucleus. This finding provides evidence that 
LDH could also be found within the nucleus, and perhaps could link the OCA-S complex 
to the redox state of the cell. Thus, it is important to determine how disruptions to LDH 
can impact the transcription of certain factors in the cell (Zheng, Roeder, & Luo, 2003).  
 Interestingly, the translocation of LDHA into the nucleus has been reported all the 
way back into last century. However, the purpose and the mechanism of this translocation 
has yet to be elucidated. One study identified a nucleic acid helix-destabilizing protein as 
Lactate Dehydrogenase-5, commonly known as Lactate Dehydrogenase A (Williams, 
Reddigari, & Patel, 1985). This finding shows the possibility of biological proteins 
having multiple roles that may depend on the current location of the protein. Another 
related study showed again that a low-salt-eluting single stranded DNA (ssDNA) binding 
protein derived from a mouse myeloma is identical to a mouse LDHA subunit. This was 
determined through analysis of identical apparent molecular masses and the cross-
reactions between both mouse and bovine LDHA subunits (Sharief, Wilson, & Li, 1986). 
Furthermore, it has been found that Lactate Dehydrogenase functions as a single-stranded 
DNA binding protein that specifically affects the DNA-polymerase-alpha primase 
complex. This was proven via testing the binding preference of the LDH to ssDNA to 
double stranded DNA (dsDNA) and LDH was shown to have a 300 fold affinity for 
binding the ssDNA (Grosse, Nasheuer, Scholtissek, & Schomburg, 1986).  
 9 
 It has been found that LDHA functions outside of its glycolytic role (Seki & 
Gaultier, 2017). Specifically, it has been found to increase the invasion potential of 
cancer cells, provide resistance to anoikis, as well as increase the metastatic capability of 
the tumor. It has been postulated that the phosphorylation of specific residues on LDHA 
cause increased activity and the negative effects. Specifically, it was found that 
phosphorylation of Tyrosine 10 (Y10) was completed by two kinases, HER2 and Src. 
This phosphorylation and therefore increased LDHA activity was found to correlate with 
breast cancer tumors that were metastatic. Importantly, it was shown that inhibition of 
these two kinases decreased LDHA activity and limited the invasion capability, anoikis 
resistance, and metastatic potential (Jin et al., 2017).  
 Because of LDHA’s important role converting pyruvate to lactate, it has earned 
the distinction of being a checkpoint of anaerobic glycolysis. It is also found to be 
elevated in many different cancer types, thereby implicating it as a potential diagnostic or 
therapeutic target for the inhibition of cancer (Miao, Sheng, Sun, Liu, & Huang, 2013). 
Some studies have found success in reducing tumor growth in vitro through the inhibition 
of a glucose transporter and LDHA (Ooi & Gomperts, 2015) In pancreatic cancers, it was 
found that acetylation status determined the activity of LDHA. This is in contrast to 
phosphorylation playing an important role in the activation of LDHA in other forms of 
cancer. Normally, LDHA is acetylated and therefore inhibited, however pancreatic 
cancers have a reduced amount of acetylation of LDHA and subsequently increased 
protein levels of LDHA. A genetic study investigating Tamoxifen-resistant breast 
carcinomas used genetic clustering to determine the gene expression of these carcinomas. 
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What was found was that LDHA was upregulated in these conditions, pointing to 
LDHA’s potential importance in drug resistance (Jansen et al., 2005). Interestingly, 
LDHA’s role in the progression of pituitary adenomas has also been studied. In this 
cancer type, it was found that the highly invasive pituitary adenomas exhibited 
significantly raised levels of both LDHA mRNA and protein expression. This study also 
utilized the LDHA inhibitor Oxamate to successfully decrease the invasive and 
proliferative ability of primary pituitary adenoma cell cultures. This demonstrated the use 
of Oxamate in an in vivo situation to inhibit LDHA, demonstrating its potential viability 
(An et al., 2017).  
 Significantly, LDHA has been implicated in the tumor’s ability to evade the 
immune system and supply the tumor with resistance to chemotherapeutic agents. A 
recent study showed that LDHA granted the tumor the ability to evade the immune 
system. Through looking at the effects of LDHA expressed by macrophages in a murine 
lung carcinoma model, it was determined that LDHA and lactate expressions by the 
macrophages drove T-cell immunosuppression. It was found that specific deletion of 
LDHA in the myeloid cells promoted a tumor suppressive phenotype of macrophages 
(Seth et al., 2017). This study confirmed the viability of targeting LDHA in combination 
with other drugs as a productive treatment for cancer therapy. Drug resistance is a major 
concern when dealing with cancer cells. Studies have demonstrated that LDHA in 
combination with HIF1A in multiple myeloma cells contributes to drug resistance. 
Furthermore, this study showed through the inhibition of LDHA and HIF1A that 
sensitivity of the cancer cells to therapeutic agents was restored. Additionally, knock 
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down of LDHA restored sensitivity to the therapeutic agent in drug resistant tumor cells, 
while gain of function studies using LDHA and HIF1A caused drug resistance in cell 
lines previously sensitive to therapeutic agents (Maiso et al., 2015). Similarly, another 
study looking at ErbB2-positive breast cancer found that increased glycolysis through 
heat shock factor 1 and LDHA contributed to resistance to a therapeutic agent (Zhao et 
al., 2009). Furthermore, it was shown that specific inhibition of glycolysis and therefore 
LDHA increased the therapeutic efficacy of the therapeutic agent in the treatment of 
ErbB2-positive breast cancers. It was found that ErbB2 upregulated both LDHA and heat 
shock factor 1. It was through ErbB2 dependent upregulation of heat shock factor 1 that 
caused heat shock factor 1 to bind to the LDHA promotor and therefore increase LDHA 
expression. Furthermore, inhibition of glycolysis and of LDHA specifically through 
Oxamate showed selectively inhibited growth of the ErbB2 cells (Zhao et al., 2009). 
These results showed the impact that LDHA has on the invasive potential of the cancer 
cell and the potential to decrease that potential. Another study showed the high glycolytic 
activity of melanomas resulted in an increased acidification of the tumor 
microenvironment. This acidification had the effect of activating a GPCR-dependent 
expression of ICER, which is a transcriptional repressor, in tumor-associated 
macrophages. This expression caused a shift in the functional polarization of the 
macrophages into a non-inflammatory phenotype, which not only contributed to tumor 
growth, but also assisted with immunoevasion (Bohn et al., 2018).  This increased 
acidification was found to have mostly come from the build-up of lactic acid production, 
caused by LDHA. Importantly, another study found that by using bicarbonate to 
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neutralize the acidic microenvironment around the tumor, there was improvement in the 
effectiveness of immunotherapy for some solid tumors (Pilon-Thomas et al., 2016). This 
is useful because if this treatment has already been shown effective, then blockage of 
tumor acidity on the upstream side might prove to be an effective treatment strategy. 
Other studies have sought to identify compounds that exert inhibitory effects against 
LDHA, even identifying a compound with an IC50 of 0.36 uM (Li, Xiao, & Zhao, 2017). 
 Small Cell Lung Cancer (SCLC), is an epithelial cancer that comprises about 15% 
of all lung cancers, but it displays unique features that distinguish it from non-small cell 
lung cancer (NSCLC). Notably, SCLC is typically a neuroendocrine tumor, while still 
maintaining some important heterogeneity in cell type. There are several important 
neuroendocrine markers found in SCLC most importantly including: Achaete-scute 
homologue 1 (ASCL1) which is a transcription factor and ASCL1, which is responsible 
for induction of neuronal and neuroendocrine differentiation. Importantly, neurogenic 
differentiation factor 1 (NEUROD1), is a master regulator of neuronal expression that 
works in combination with ASCL1. Interestingly, NEUROD1 targets the oncogene 
MYC, which in turn is able to activate LDHA as LDHA is a MYC responsive gene 
(Zeller, Jegga, Aronow, O’Donnell, & Dang, 2003). Recently, it has been found that Re1 
silencing transcription factor (REST) has an important role in SCLC by repressing the 
expression of the neuroendocrine differentiation of cells.  SCLC presents with swift 
tumor growth, high vascularity, and introduces instability into the genome. Additionally, 
in almost every single SCLC, there is inactivation of the tumor suppressors TP53 and 
RB1, which seem to be the most important factors ins preventing the SCLC phenotype 
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from developing. Unfortunately, SCLC is also a highly metastatic cancer type and while 
SCLC often responds well initially to chemotherapy, seemingly without fail, it typically 
relapses quickly while obtaining resistance to further chemotherapeutic treatment (Y. 
Chen, Yang, Xu, Cao, & Chen, 2017). Until recently, there have been very few notable 
developments in treatment practices for SCLC as the standard of care has been doublet 
chemotherapy using a platinum agent and etoposide (Rudin et al., 2015). Another notable 
difficulty of dealing with SCLC both clinically and approaching it from the research side 
is the lack of available tumor samples. SCLC is a highly metastatic cancer type and its 
discovery can often be at a secondary site. This, along with the fact that the tumor 
composition can vary in the amount of neuroendocrine and non-neuroendocrine cells 
present make using cell lines difficult as they are not always faithful recreations (Gazdar, 
Bunn, & Minna, 2017).  While there is not much use of Induced Pluripotent Stem Cells 
(iPSCs), one study reported ASXL3, a PRC2-associated protein, as a novel epigenetic 
target for treatment of SCLC (Shukla et al., 2017).  
 In lung cancers, LDH has been used as a prognostic marker for the prognosis of 
the disease. Data from one study suggested that patients that had a higher level of serum 
LDH prior to treatment were more likely to have worse overall survival percentages 
(Deng, Zhang, Meng, Zhou, & Li, 2018). Similarly, another study sought to validate 
LDH as a marker to monitor treatment response in SCLC. The results from this study 
showed that elevated levels of LDH corresponded with a higher likelihood of disease 
progression and that again, high initial levels of LDH correlated with a decreased 
probability of patient survival (C. Chen, Zhu, & Huang, 2018). Intriguingly, another 
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method for measuring survival in lung cancer patients is to look at circulating tumor cell 
count (CTC). LDH has been previously thought to be involved with the metastatic 
capabilities of cancers. One study determined that higher amounts of CTCs caused 
decreased progression free survival and overall survival. It is highly likely that LDH 
plays a role in this process, and the correlation between increased CTC and decreased 
survivability indicate that targeting LDH in SCLC may be a potential successful 
therapeutic avenue.  
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SPECIFIC AIMS 
 The purpose of this thesis is to investigate the role of Lactate Dehydrogenase A 
(LDHA) in the promotion of Small Cell Lung Cancer (SCLC). SCLC is a highly 
metastatic cancer that easily spreads to the brain. It is not known what causes the highly 
invasive nature of this cancer type. LDHA has been thought to play a role in the ability of 
the tumor to metastasize. In this study we hope to determine whether there is a similar 
role of LDHA in SCLC and if the removal of LDHA from the cell line attenuates the 
metastatic capacity of the tumor. Additionally, based on previous literature and our 
observations, we sought to determine what factors stimulated the translocation of LDHA 
from the cytoplasm into the nucleus. 
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METHODS 
 
Image Generation 
Pathway images were generated using PathVisio and Inkscape. Other photo editing and 
combination was done using Microsoft PowerPoint or Excel. Graphical representations 
were created in GraphPad Prism 5.  
Design of guide RNA 
Three exon regions for LDHA were chosen to be targeted. Long exons close to an ATG 
sequence were chosen. Feng Zhang’s groups work was used to identify sequences, 
accessed at http://crispr.mit.edu/. For each exon region, both a forward and reverse 
primer were created. 
Cloning of guide RNA in pCRISPRv2 Vector 
The backbone was created using 4 g –pCRISPRv2, 4 L of 10x NEB 3.1, 2 L BsmIB 
and H2O to fill a final volume of 40 L. This was left to incubate at 37°C for 4 hours. 
After incubation, 1 L CIP was added and this mixture was then incubated for 1 hour at 
37°C. To purify the fragment, a Qiaquick Kit was used. To phosphorylate and anneal the 
oligomers, each oligomer was prepared by combining 180 L H2O with 10 L of 100 M 
oligomer 1 and 10 L of 100 M oligomer 2. Then, 1 L of the oligomer preparation was 
added to 20 L of H2O and after this, 2 L of 10x T4 ligase buffer containing ATP was 
added along with 1 L of T4 PNK. Next, 80 L of 1x T4 ligase buffer was added to each 
tube. The mixtures were then run in a thermocycler according to the following presets: 
37°C for 45 minutes, then 95°C for 5 minutes and slowly dropped in temperature to 
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37°C. Ligation was achieved by combining the following mixture: 3 L H2O, 5 L of 2x 
quick ligase buffer, 1 L of pCRISPR v2 (about 30 ng), 1 L of the diluted oligomer, and 
1 L of T4 ligase. This was then incubated for 30 minutes at room temperature. It is 
important to add the diluted oligomer last to the mixture. Transformation of the ligated 
oligomer was completed by the following process. First, by adding 10 L of the ligation 
product to 100 L of competent cells and placed on ice for 20 minutes. Second by 
placing the mixture in a 42°C water bath for 2 minutes, then back on ice for 2 minutes, 
then adding 600 L of LB medium and incubating for 30 minutes at 37°C. After this 
incubation, half of the volume was plated in drops and then spread using a bent glass 
Pasteur pipette.   
Screening of Positive Clones of gRNA 
Preparation of the template was completed by addition of 22.5 L water to a PCR tube 
for each clone. 5 clones of each ligation were picked. Clones were picked using a 20 L 
tip and resuspended in the water in each PCR tube. Next, 100 L LB media with 
ampicillin was added to a sterile 96 well plate for each of the picked clones. 10 L of the 
E. coli suspension was added and incubated at 37°C to save as a “back-up”. For the PCR, 
the E. coli samples were boiled for 10 minutes at 95°C. While this was boiling, the 
following mixture was created for each template: 2.5 L 10x B, 0.6 L 10 mM dNTPS, 
0.6 L CRISPR forward and reverse, 0.3 L Taq polymerase, 8.5 L H2O. After boiling, 
12.5 L of each boiled template was added to a PCR tube containing this mixture. For the 
PCR cycle, it was run at 95°C for 3 minutes, then 40 cycles of 95°C for 30 seconds, 50°C 
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for 30 seconds, 72°C for 30 seconds. Lastly the samples were held at 72°C for 5 minutes. 
The PCR products were run on a 1.5% gel to assess the efficiency. Two of the best 
products for each template were selected and inoculated in 5 mL of LB-Ampicillin for 
use in the Qiagen miniprep kit. The prepared samples were then sent for sequencing. 
Preparation of Plasmids for LDHA expression 
First, the CDC region of LDHA was analyzed and restriction enzymes were chosen. 
EcoR1 and NotI restriction enzymes were chosen (New England BioLabs). The 
sequences of the Forward EcoRI and Reverse NotI are as follows: 
EcoR1 F GGAATTCATGGCAACTCTAAAGGATC 
NotI R TTAAAATTGCAGCTCCTTTGCGGCCGCTAAACTAT 
 
Table 1: List of Primers used for the generation of Plasmids used for transfection of 
LDHA. EcoR1 and NotI were chosen due to other possible enzymes displaying cutting 
sites that would inactivate the transfected plasmid. 
 
After receipt of the primers, 100 L of RNase Free water was added to create a working 
primer. The primers were then used in Reverse Transcription PCR to generate a PCR 
product to produce useable LDHA overexpression plasmids. cDNA generated from 
MCF-7 RNA was used in the Reverse Transcription PCR. 5 Plasmids were chosen to 
create 5 separate backbones, pCDH Puromycin, pCDH Flag Puromycin, pCDH COP 
GFP, pCDH Neomycin, and pCDH RFP Neomycin. From these, pCDH Puromycin, 
pCDH Flag Puromycin, and pCDH COP GFP were chosen to continue the experiments. 
The plasmids were first grown in a 3 mL volume of LBA
+
 medium and placed in a 
shaking incubator at 200 RPM at 37°C for 6 hours. After 6 hours, these cultures were 
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transferred to 100 mL total volume and placed back in the shaking incubator overnight at 
the same conditions. The plasmids were extracted the next morning using a Qiagen Maxi 
Kit. Following extraction, the plasmids were then purified on an 8% Agarose gel and 
subsequently extracted using a QIAquick Gel Extraction Kit (Qiagen). Following 
purification, the plasmids were ligated using the following procedure. To a 1.5 mL 
Eppendorf tube, 5 L of 2x quick ligase buffer, 1 L of plasmid backbone (pCDH Puro, 
pCDH Flag Puro, or pCDH COP GFP), 1 L of hLDHA PCR product, and 1 L of T4 
ligase were added and incubated at RT for 30 minutes. Following ligation bacterial 
transformation was completed to obtain positive clones according to the following 
procedure: 10 L of the ligation product was added to 100 L of competent cells and 
incubated on ice for 20 minutes. After this incubation, the mixture was quickly 
transferred into a 42°C water bath to achieve heat shock for 2 minutes, then placed back 
on ice for 2 minutes. 600 L of LB medium was added to the mixture and incubated for 
30 minutes at 37°C. After this incubation, the mixture was spun down and carefully 
decanted and the bacterial pellet was resuspended in 100 L of LB medium and plated 
onto an LBA
+
 agar plate. This plate was then incubated overnight at 37°C and clone 
growth was assessed 24 hours later and 5 large clones were picked. These clones were 
then expanded into 3 mL of LBA
+
 medium and grown overnight. The following morning 
the plasmids were extracted using a Qiagen Miniprep kit. The extracted plasmids were 
then analyzed for protein concentration. The two plasmids with the highest protein 
concentration were selected and sent for sequencing at the Harvard Medical School 
Biopolymers Facility. 
 20 
Cell Culturing 
MCF-7 Cells were cultured in DMEM, with 10% fetal bovine serum (FBS) as well as 1% 
penicillin and streptomycin. Cells were incubated in an atmosphere of 5% CO2, and 95% 
O2 at 37
o
C and humidified. DMEM, penicillin, and streptomycin were purchased from 
Fischer Scientific while the FBS was purchased from Atlanta Biologics. Cell lines were 
subcultured every 3 days. 
Mouse SCLC cell lines were cultured in RPMI, with 10% fetal bovine serum (FBS) as 
well as 1% penicillin and streptomycin. Cells were incubated in an atmosphere of 5% 
CO2, and 95% O2 at 37
o
C and humidified. RPMI, penicillin, and streptomycin were 
purchased from Fischer Scientific while the FBS was purchased from Atlanta Biologics. 
Cell lines were subcultured every 3 days. 
Western Blotting 
Samples were prepared in equal concentrations to be run on an 8% Tris-Glycine gel. All 
samples were run for 15 minutes at 80 A, then 15 minute intervals of 150 A until ready to 
transfer and a last 20-minute interval of 50 A. Transferring was done onto a nitrocellulose 
membrane run at 400 mA for 1.5 hours at 4°C. After transferring, the membrane was 
blocked for 1 hour at RT using 5% milk in TBST. The primary antibody was incubated 
overnight at 4°C on a shaker. Following the incubation, three washes of 5 minutes with 
TBST were completed before the HRP Conjugated secondary antibody was incubated for 
1 hour at RT. The membrane was again washed three times for 5 minutes each with 
TBST. The membrane was developed using Hyglo® Quick Spray and a dark room.  
Protein Extraction and Concentration Detection 
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To extract protein from cells, the cells were aspirated and washed with PBS. Then a lysis 
buffer of 2% SDS was added to the cells. This mixture was then boiled for 20 minutes at 
100°C. Protein concentration was detected using the Pierce™ BCA Protein Assay Kit. 
RNA Extraction 
Cells were aspirated and 800 L of Trizol was added directly to the cells and incubated 
for 1 minute at RT. This mixture was then mixed in a pipette and transferred to a 
microcentrifuge tubule and frozen. At a later time the RNA samples were thawed and 
vortexed. 200 L of chloroform was added to each sample and vigorously mixed. 
Samples were then centrifuged for 5 minutes at 12,000 g at 4°C. Aqueous phase was 
transferred to a fresh microcentrifuge tube and 500 L of isopropanol was added. 
Mixture was then incubated at RT for 10 minutes. Next the mixture was centrifuged for 
10 minutes at 12,000 g at 4°C. Pellet was then washed with 800 L of 70% RNase free 
Ethanol. Sample was then spun down and supernatant was removed.  Pellet was dried at 
RT and then dissolved in RNase free water between 15 and 50 L depending on pellet 
size to maintain similar concentrations. Concentration was measured using a NanoDrop 
spectrophotometer (Thermo Scientific). 
Virus Transfection and Infection  
Desired plasmids were transfected into Human Embryonic Kidney (HEK) 293T cells 
using Lipofectamine 2000 to create the required lentivirus. The medium was changed 
after 6 hours. 48 hours after initial transfection the lentivirus was harvested and the new 
cells were infected. 48 hours post infection the cells were selected using 2 g/mL 
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puromycin. Cells were grown to full density and subcultured once before experiments 
were completed. 
Lactate Studies 
Cells were cultured according to previously listed methods and then plated on a 12 well 
plate with a glass sheet on the bottom in two cell numbers. Cells were counted with a 
hemocytometer and light microscope. Two time periods of lactate incubation were used, 
24 hours and 48 hours.  
Immunofluorescence Staining 
Cells were seeded at either twenty-four or forty-eight hours prior to fixation. Fixation was 
done with a 4% solution of paraformaldehyde in in phosphate buffered saline. Cells were 
then permeabilized and blocked in a solution of 0.5% Triton X-100 and 3% BSA in 
phosphate buffered saline at pH 7.5 for 30 minutes. Next, the cells were incubated with 
the primary antibody for 1 hour at room temperature. All antibodies were diluted in a 
solution of 1% BSA in phosphate buffered saline. Cells were then rinsed and washed 
with 0.1% phosphate buffered saline Triton X-100 (PBST). Next the cells were incubated 
with the secondary antibody for 1 hour at room temperature in complete darkness. Cells 
were then rinsed with PBST and mounted with Fluoromount-G medium and visualized 
via microscope. 
Soft Agar Assay 
For the soft agar assay, two layers of agarose were prepared in a 6 well plate. The bottom 
layer consisted of 1% agarose, which was diluted down from a 3% agarose stock with the 
medium of use for the cell line. This layer was incubated at 4°C to allow solidification. 
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The top layer was created by combining 3% agarose with 10% fetal bovine serum 
fortified medium, and 100% fetal bovine serum. This mixture initially created a 0.8% 
agarose mixture and was diluted with the correct number of cells in a 1:1 ratio to create a 
final concentration of 0.4% agarose. After plating the cells, the 6 well plate was placed 
into the 4°C fridge to solidify for 30 minutes before it was moved to the 37°C incubator 
with 5% CO2. 500 L of complete media was added every four days to the plated cells. 
After visual growth was visualized, the cells were stained with 1 mL p-
iodonitrotetrazolium violet at 37°C overnight. Next, the plates were scanned and the 
stained colonies were counted.  
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RESULTS 
Validation of pCDH Plasmids 
Table 2: Concentration of pCDH Plasmids before ligation. Concentrations of pCDH 
Plasmids after initial growth, before ligation of LDHA PCR product with plasmid. High 
concentrations of plasmid were extracted with MaxiKit from Qiagen to have enough 
plasmid for other experiments and have sufficient stock. 
pCDH Plasmid Concentration (ng/L) 
pCDH Neomycin 1202.1 
pCDH Puromycin 1126.9 
pCDH RFP Neomycin 1420.7 
 
Validation of hLDA sgRNA in MCF-7 cells 
 
To ensure that the sgRNA for hLDHA was correct and accurate, the knock-out of LDHA 
was first assessed in MCF-7 cells. Protein concentration and subsequent western blot 
were completed to analyze knock-out efficiency. 
Figure 3: Protein detection of hLDHA sgRNA in MCF-7 cells. Standard Curve for 
protein detection of hLDHA sgRNA in MCF-7 cells. Standards used were 0, 2, 4, 6, 8, 
12, 16, and 20 g/mL of BSA.  
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Table 3: Protein Concentration of MCF-7 hLDHA sgRNA Cells. Protein 
concentration of collected cells after 7 days, with 1 subculturing done in a 1:4 ratio. 
CRISPR V2 serves as the control cell line, and based on the protein concentration of 
hLDHA sgRNA 1 and 3 show that there is decreased growth of cell lines with hLDHA 
knocked out.  
 
Cell Modification Protein Concentration (g/mL) 
MCF-7 CRISPR V2 13.23 
MCF-7 hLDHA sgRNA-1 9.77 
MCF-7 hLDHA sgRNA-2 13.61 
MCF-7 hLDHA sgRNA-3 10.82 
 
 
Figure 4: Western Blot of 2-day Puromycin Selection of MCF-7 Cells. A represents 
the Actin internal control while B 1-4 is MCF-7 cells with the following mutations: 1: 
CRISPER V2-puromycin, 2: hLDHA sgRNA 1-puromycin, 3: hLDHA sgRNA 2-
puromycin, hLDHA sgRNA 3-puromycin.  
 
 
 
 
 
 
 
 
 
 
 
 
Human LDHA 
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1                 2               3               4 
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Validation of hLDA sgRNA in A549 and MCF-7 cells 
 
Figure 5: Western Blot of hLDHA-KO in MCF-7 and A549 Cells. A: Actin internal 
control, B: hLDHA. 1: MCF-7 CRISPR V2, 2: MCF-7 hLDHA sgRNA 1, 3: MCF-7 
hLDHA sgRNA 2, 4: A549 CRISPR V2, 5: A549 hLDHA sgRNA 1, 6: A549 hLDHA 
sgRNA. Western blot shows confirmation of hLDHA knock-out efficiency in MCF-7 and 
A549 constructed cell lines after 1 week puromycin selection 
 
LDHA Staining in A549 Lung Carcinoma Cells 
 
Figure 6: IF Staining of A549 WT Cells in Full Medium. LDHA (green) staining in 
A549 wild type cells fixed after 24 hours of growth in full media. DAPI (blue) staining 
shows the nucleus of the cell. A: LDHA staining only, zoomed out view, B: DAPI 
staining only, zoomed out view, C: Merged LDHA and DAPI staining, zoomed out view, 
D: LDHA staining only, zoomed in view, E: DAPI staining only, zoomed in view, E: 
Merged LDHA and DAPI staining, zoomed in view. Objective magnification is 60X, 
with a total magnification of 600X. 
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Figure 7: IF Staining of A549 WT Cells with Lactate Treatment. LDHA (green) 
staining in A549 wild type cells treated with Lactate (10 mM) for 24 hours and fixed. 
DAPI (blue) staining shows the nucleus of the cell. A: LDHA staining only, zoomed out 
view, B: DAPI staining only, zoomed out view, C: Merged LDHA and DAPI staining, 
zoomed out view, D: LDHA staining only, zoomed in view, E: DAPI staining only, 
zoomed in view, E: Merged LDHA and DAPI staining, zoomed in view Objective 
magnification is 60X, with a total magnification of 600X. 
 
Figure 8: IF Staining of A549 CRISPR V2 Cells in Full Medium. LDHA (green) 
staining in A549 CRISPR V2 cells treated with full media for 24 hours and fixed. DAPI 
(blue) staining shows the nucleus of the cell. A: LDHA staining only, zoomed out view, 
B: DAPI staining only, zoomed out view, C: Merged LDHA and DAPI staining, zoomed 
out view, D: LDHA staining only, zoomed in view, E: DAPI staining only, zoomed in 
view, E: Merged LDHA and DAPI staining, zoomed in view. Objective magnification is 
60X, with a total magnification of 600X. 
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Figure 9: IF Staining of A549 CRISPR V2 Cells with Lactate Treatment. LDHA 
(green) staining in A549 CRISPR V2 cells treated with Lactate (10 mM) for 24 hours and 
fixed. DAPI (blue) staining shows the nucleus of the cell. A: LDHA staining only, 
zoomed out view, B: DAPI staining only, zoomed out view, C: Merged LDHA and DAPI 
staining, zoomed out view, D: LDHA staining only, zoomed in view, E: DAPI staining 
only, zoomed in view, E: Merged LDHA and DAPI staining, zoomed in view. Objective 
magnification is 60X, with a total magnification of 600X. 
 
 
Figure 10: IF Staining of A549 hLDHA sg1 in Full Medium. LDHA (green) staining 
in A549 hLDHA sgRNA in full media. A: LDHA staining only, zoomed out view, B: 
DAPI staining, zoomed out, C: Merged LDHA and DAPI staining, zoomed out view, D: 
LDHA staining only, zoomed in view, E: DAPI staining only, zoomed in view, E: 
Merged LDHA and DAPI staining, zoomed in view. Objective magnification 60X, total 
magnification of 600X.  
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 Immunofluorescence was performed on A549 hLDHA sgRNA 1 cells to confirm 
the population of cells where LDHA was knocked out. The DAPI serves as the 
denominator. The lack of hLDHA staining clearly shows that the sgRNA 1 was 
successfully integrated into the cell line. 
 
 
Translocation of LDHA into the nucleus 
 
Figure 11: Translocation of LDHA into the Nucleus. LDHA (Green), and DAPI (Blue) 
staining in A549 Wild type cells (A, B, C) and A549 CRISPR V2 cells (D, E, F). These 
translocation pictures were found in the cells treated with full media and no lactate 
treatment. Objective magnification 60X, total magnification of 600X.  
 
 
 The translocation of LDHA into the nucleus was found to occur in both the A549 
wild type cells as well as the A549 CRISPR V2 cells. These translocations occurred in 
both the no lactate treatment groups as well as the lactate treatment groups, with the 
lactate treatment having little to no effect on the translocation amount. 
 
A B C 
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Concentration of lactate in different tumor samples 
Figure 12: Concentration of Lactate in Different Sized Tumors. Concentration of 
lactate found in tumors from size 0 mm to greater than 9 mm, as well as different 
metastases of the tumors. As the tumor size increased, there was a higher concentration of 
lactate. Additionally, in the tumors sampled from a secondary site, there was a higher 
concentration of lactate, independent of size. 
 
 
 The general trend found in the presented data shows that as the tumor increased in 
size, there was more extracellular lactate present in the sample. Additionally, samples 
taken from a secondary site tended to have an increased concentration of lactate. 
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SCLC in 716T2S cells derived from mouse model 
 
Figure 13: Expression of LDHA in 716T2S Cell Line. Western Blot of Four Mouse 
SCLC cell lines, 1 and 2 are cell lines with high LDHA expression and 3 and 4 are cell 
lines with low LDHA expression. GAPDH and ACTIN served as internal controls for the 
expression of LDHA.  
 
Figure 14: Lactate Concentration in Mouse SCLC Cells. Detection of intracellular 
Lactate concentration in the high LDHA and low LDHA expressing cell lines. Expression 
was normalized to a wild type control such that relative expression could be graphed. 
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Figure 15: Western Blot of LDHA-KO in Mouse SCLC Cells. Western blot of 716T2S 
cell lines with the two separate LDHA sgRNAs to show the knockout of LDHA. Actin 
served as the internal control and the CRISPR V2 cell line served as the cell control. 
 
 
Figure 16: Lactate Concentration in 716T2S-LDHA-KO Cells. Knock out of LDHA 
in a high LDHA expressing cell line, 716T2N. CRISPR V2 was used as the control for 
the transfection of the LDHA sgRNA1 and 2. *** means p < .05. Two separate LDHA 
sgRNAs were designed and transfected into the cells.  
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Figure 17: Colony Formation of 716T2S-LDHA-KO cells. Soft Agar Assay of 716T2S 
cell lines. Left: 716T2S CRISPR V2 control cell line, Middle: 716T2S LDHA-sgRNA 1 
cell line, Right: 716T2S LDHA-sgRNA 2 cell line.  
 
 
Figure 18: Colony Counting of 716T2S-LDHA-KO Cells. Count of the colony growth 
from the soft agar assay of the 716T2S CRISPR V2, 716T2S LDHA-sgRNA 1, 716T2S 
LDHA-sgRNA 2 cells. *** means p < .05. 
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Figure 19: Cellular Growth of 716T2S-LDHA-KO Cells. Graphical representation of 
the growth inhibition caused by the absence of LDHA in the 716T2S cell lines. Cells 
were analyzed in twenty-four hour increments for seven days to analyze growth.  
 
 
 
 
SCLC in 728N cells derived from mouse model  
 
Figure 20: Western Blot of 728N-LDHA-KO Cells. Western blot showing the 
efficiency of knockout of LDHA in the mouse model derived 728N cell line. Left: 728N 
CRISPR V2 cells, Middle: 728N LDHA sg1, Right 728N LDHA sg2. Actin served as the 
internal control. Knockout was successful in generating two stable clone cell lines for 
experiments. 
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Figure 21: Colony Formation of 728N-LDHA-KO Cells. Soft Agar Assay of 728N 
mouse model derived cell line. Left: 728N CRISPR V2, Middle: 728N LDHA sg1, Right: 
728N LDHA sg2. Colony growth was greatly inhibited by the lack of LDHA in the cell. 
 
 
 
Figure 22: Colony Counting of 728N-LDHA-KO Cells. Graphical representation of the 
Colony number found in the Soft Agar Assay of the mouse model derived 728N cells. 
Left: 728N CRISPR V2, Middle: 728N LDHA sg1, Right: 728N LDHA sg2. *** means 
p < .05 
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Figure 23: Cellular Growth of 728N-LDHA-KO Cells. Results of the MTT assay. 
Black line: Growth of 728N CRISPR V2 cells, Red line: Growth of the 728N LDHA sg1 
cells, Blue line: Growth of 728N LDHA sg2 cells. Growth of the LDHA knockout cell 
lines was impacted greatly by the lack of LDHA in the cell. *** means p < .05. 
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DISCUSSION 
 
 The treatment of  SCLC continues to provide a difficult challenge, as no targeted 
therapy has been developed even as combinations of immunotherapy and chemotherapy 
are being implemented with various degrees of success in other cancer types. Part of the 
lack of treatment options may lie in the difficulty of obtaining primary samples of SCLC 
tumors. However, until recently, there has also been a distinct lack of research into 
SCLC. As the technology used in research continues to advance, there has been progress 
into the research of SCLC. This study sought to elucidate what role, if any, that LDHA 
had in the progression of SCLC. If there is a way to successfully decrease the vitality of a 
cancer cell by targeting LDHA, that provides the basis for using either an inhibitor of 
LDHA or eventually the knock-out of LDHA using gene editing technology. By using the 
inhibition or removal of LDHA in combination with other targeted therapies, this might 
improve the success rates of cancer therapy. LDHA knock-out studies were done in 
mouse SCLC cell lines, which are in some ways similar, but in others are different from 
human SCLC cell lines. The difficulty in using human SCLC cell lines is that currently 
there is a lack of samples as it is a highly metastatic cancer and that often times the 
complexity of the cell lines is rudimentary compared to the actual tumor cells. As 
mentioned earlier, SCLC is a highly heterogenic cancer type composed of both 
neuroendocrine and non-neuroendocrine cells. This ratio is subject to change based on 
the tumor’s microenvironment and this increases the difficulty of culturing a completely 
faithful cancer cell line.  
 
 38 
 For the generation of sgRNA for LDHA the primers were first validated in MCF-
7 and A549 cell lines. The two best sgRNAs were selected to continue experiments. The 
purpose of using MCF-7 and A549 cell lines to validate the primers was to have two 
different types of cancer cell lines to validate the knock-out of hLDHA. In the MCF-7 
cell lines it was shown that there was a slight decrease in the amount of growth of the cell 
lines after hLDHA knock-out compared to wild type and CRISPR V2 controls. This 
indicated that there may be decreased viability of the cancer cell lines without LDHA 
present. Lactate studies were only performed on the A549 cell lines due to the focus of 
the study being lung cancer and not breast cancer. 
 The lactate studies were done at two different concentrations and two different 
time points to determine which would be the best. After examination of the 
immunofluorescence staining and pH of the medium, it was determined that there was no 
significant difference between the twenty-four hour lactate treatment and the forty-eight 
hour lactate treatment. The twenty-four hour lactate treatment was then repeated again. In 
both the A549 CRSIPR V2 cells and the A549 wildtype cells, there was a slight decrease 
in the visible brightness of the LDHA staining in the lactate treated cells compared to 
control (Figures 6-10). This was expected as LDHA catalyzes the reversible reaction 
between pyruvate and lactate. It was expected that the increased lactate concentration 
would reduce the expression of LDHA as the cells attempted to maintain a stable 
microenvironment. The knock-out of LDHA in the A549 cells was very successful and 
was confirmed by both Western Blot and immunofluorescence. As there was very little 
 39 
LDHA present in the A549 hLDHA sgRNA 1 cells, there was very little effect of the 
lactate treatment on the levels of LDHA present in the cells.  
 In the lactate studies, there was an unexpected result that was found, the 
translocation of LDHA into the nucleus, as visualized in the immunofluorescence 
staining (Figure 11). Interestingly, the translocation of lactate did not seem to be caused 
by the lactate, as it was present in both the control and lactate treated cells. The number 
of translocations that were in each immunofluorescence staining was very low, and the 
majority of the translocations were found around the outside of the cell plate. This 
suggested that perhaps the translocations were more likely to occur when there was a 
lower cell count that was seeded. This proved not to be the case as there was no 
significant difference in translocations between the cells seeded at 5000 cells per 
microliter and 2500 cells per microliter. The next question that we then sought to address 
was if the translocations occurred due to some technique in the staining process. The first 
variable that we changed was the shape of the plate that the cells were seeded on. The 
original plate shape was a circle. The circular plate was then completed in tandem with a 
square cell plate. There was not a significant variation in the number of translocations 
that appeared between the circular and square pieces of cover glass. However, the 
translocations did appear at a higher frequency along the outside of the cover glass, for 
both the square and the circular experiments.  
 From the studies in mouse SCLC cell lines, several observations were made. First, 
was the amount of lactate in different sized SCLC tumors (Figure 12). As the tumors 
became larger, the amount of lactate found in the tumor also increased. This result is not 
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completely unexpected due to what is known about hypoxia in tumors. As the tumor 
increases in size, the entire tumor is not perfused to the same degree, meaning that the 
portions without a reliable blood flow will be required to undergo anaerobic respiration 
more often. The interesting result is that of the increased concentration of lactate found in 
the metastatic samples of SCLC. This indicates that there is a potential role that LDHA 
might play in increasing the metastatic capability of tumors. Previous studies have 
suggested that increased LDHA increases the amount of necessary nutrients that can be 
taken up into the cell (Miller et al., 2012). With pharmacologic intervention against 
LDHA, it may be possible to slow the metastases of tumors. Second, there were tumor 
samples that had high expression of LDHA as well as samples with low expression of 
LDHA. Unsurprisingly, the samples with higher expression of LDHA also had higher 
levels of intercellular lactate (Figure 14). As there is more of the enzyme present, it is not 
difficult to understand why there is a higher amount of lactate produced by that tumor. It 
was also found that by knocking out LDHA in both of these sample types, that the 
concentration of lactate decreased when compared to control (Figure 16). 
 Following the Soft Agar Assay, it was clear to see how the knock-out of LDHA 
inhibited the colony growth of the mouse SCLC cell lines. Compared to control there was 
significantly decreased growth of the LDHA KO cell lines. This experiment showed the 
potential therapeutic avenue that arises through treatment of SCLC by inhibiting LDHA’s 
activity in vitro. This opens up treatment of SCLC cell lines with specific LDHA 
inhibitors that could be used in a combination therapy along with other drugs target to 
SCLC. Further studies need to be continued to provide more insight into treatment of 
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SCLC, however the validation of LDHA as a potential target will help. There are 
inhibitors of LDHA that could be used in vitro, which is the next step of this research. By 
inhibiting LDHA pharmacologically it would be interesting to confirm if the colony 
growth and cellular growth of tumors is affected in the same manner. Pharmacological 
inhibition would be more suitable for clinical treatment than using genetic knock-outs, 
due to the limited effectiveness of the CRISPR-cas9 system in targeting specific sites. As 
more research is completed when looking into LDHA and its link to cancer, it is possible 
that there are novel drug designs that will be able to effectively and selectively target 
LDHA. As the development of drugs and research progresses, hopefully a manageable 
treatment for SCLC will emerge, and provide relief to a once recalcitrant disease. 
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